Memidis Pharma
Research & Development
Research & development
Our core values for developing a new product:
More effective than current treatment options
Contributing to quality of life
Fewer or no side effects
Increasing ease of use
Products in development
Future developments
| Indication | Compound | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submitted |
|---|---|---|---|---|---|---|---|
| Lichen Sclerosus | MMPX1988 |
|
|||||
Research & Development
MMPX1988
Memidis is developing a new treatment for Lichen Sclerosus. Many patients with Lichen Sclerosus do not come out of the current treatment options partly because of side effects and ineffectiveness also they do not restore the skin.
MMPX1988 is an ointment with unique mechanisms of action and has:
- Strong anti-inflammatory effect
- Restores and regenerates the skin
- Can be used continuously
Research & Development
Lichen Sclerosus
Is a chronic inflammatory disease of the skin in the genital area. The disease occurs mainly in postmenopausal women. The skin becomes porcelain-like, white and thin. The most common symptoms are atrophy of the skin, itching, burning and pain.
Lichen Sclerosus is a serious disease that has a major impact on a woman’s quality of life and sexual functioning.
In Europe, there are over 600,000 women with Lichen Sclerosus.
